PLK1 and neoplasm: To examine this, we selected genes that are overexpressed in p53-mutant human BC tumours (Miller dataset, Table S2) [28], and for which specific inhibitors are in preclinical testing: AURKA, AURKB and PLK1 (Fig. 5A).